The clock is already ticking.
In pharma commercial market access, the most expensive mistake isn’t pricing—it’s timing. If you’re a vendor selling into payer, provider, or access teams, waiting until the drug is “almost ready” can mean you’re competi…

Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Company (and Your Timeline)
In pharma, “almost ready” can be the most expensive place to be.
You’ve got a promising label, a manufacturing plan, and a launch calendar that’s been st…

Pharma procurement teams are sitting on a blind spot—and it’s costing them leverage.
If you buy drugs, negotiate contracts, or manage formularies, you already know the obvious risks: price volatility, supply constraints, and payer pressure. But there’s…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or planning a launch strategy, “patent protection” is often treated like a fixed number—years on a c…

Drug patent expiries aren’t just legal milestones—they’re commercial deadlines. And most companies treat them like a calendar event instead of a revenue strategy. The result? Missed windows, late outreach, and competitors who show up first with the rig…

Sell the line before the patent breaks. That’s the playbook solid-dose equipment suppliers are increasingly using to win the next wave of generic and biosimilar manufacturing—before the market even fully “opens.”
Here’s the agitation: most business dev…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The “Smarter Monopoly” Debate Is Here—And It’s About to Shape Drug Prices for Years
Drug policy has a way of sounding abstract—until you look at the mechanics. A new analysis from DrugPatentWatch frames a question that’s quickly moving from think-tank …

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The biggest mistake in biologics business development isn’t pricing—it’s timing.
In the world of sterile manufacturing, the “cliff” is los…

Generic competition is supposed to be the end of the story. In practice, it’s often the beginning of a new chapter—one written in reformulations, new indications, and carefully timed patent strategies.
Drug Patent Watch’s piece on how companies “squeez…